1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Nasdaq Copenhagen  -  11:12 2022-07-01 am EDT
784.60 DKK   -0.33%
06/30NOVO NORDISK A/S : The technical configuration is positive
06/29European ADRs Move Slightly Higher in Wednesday Trading
MT
06/28NOVO NORDISK : UBS lowers its rating to Sell
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVO NORDISK : Barclays gives a Buy rating

05/12/2022 | 07:02am EDT

Already positive, the research from Barclays and its analyst Emily Field still consider the stock as a Buy opportunity. Previously set at DKK 850, the target price has been slightly modified to DKK 875.


© MarketScreener with dpa-AFX Analyser 2022
All news about NOVO NORDISK A/S
06/29European ADRs Move Slightly Higher in Wednesday Trading
MT
06/28NOVO NORDISK : UBS lowers its rating to Sell
MD
06/27BNP Paribas Exane Upgrades Novo Nordisk to Neutral From Underperform
MT
06/27Novo Nordisk A/S – Share repurchase programme
GL
06/24NOVO NORDISK : UBS sticks Neutral
MD
06/24NOVO NORDISK : Goldman Sachs keeps its Buy rating
MD
06/23Camp Huronda welcomes back campers for a long-awaited reopening and unveils the new Ins..
AQ
06/22Novo Nordisk, Echosens Tie Up to Increase Early Diagnosis of Chronic Metabolic Liver Di..
MT
06/22Echosens and Novo Nordisk Announce Partnership to Increase Awareness and Advance Early ..
CI
06/21NOVO NORDISK A/S : Current Report by Foreign Issuer (Form 6-K)
PU
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2022 168 B 23 500 M 23 500 M
Net income 2022 53 541 M 7 487 M 7 487 M
Net cash 2022 1 841 M 257 M 257 M
P/E ratio 2022 33,3x
Yield 2022 1,47%
Capitalization 1 780 B 249 B 249 B
EV / Sales 2022 10,6x
EV / Sales 2023 9,27x
Nbr of Employees 49 295
Free-Float 69,6%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 787,20 DKK
Average target price 813,00 DKK
Spread / Average Target 3,28%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S7.10%251 273
JOHNSON & JOHNSON3.46%467 100
PFIZER, INC.-13.73%294 179
ELI LILLY AND COMPANY16.94%291 859
ROCHE HOLDING AG-15.97%272 586
ABBVIE INC.13.12%270 651